Boston, MA 的 鱗狀細胞癌 臨床試驗
8 項針對 鱗狀細胞癌 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
招募中3 期
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Tufts Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Toripalimab With Chemotherapy for Sinus Cancer
招募中2 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
招募中2 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
招募中3 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
招募中1 期
- Dana Farber/Partners Cancer Care Inc, Boston
其他城市的 鱗狀細胞癌 試驗
- Pittsburgh, PA10 項研究
- Los Angeles, CA8 項研究
- Houston, TX7 項研究
- New York City, NY7 項研究
- Nashville, TN7 項研究
- Atlanta, GA5 項研究
- Durham, NC4 項研究
- Arlington, VA4 項研究
- Tampa, FL4 項研究
- Washington, DC4 項研究
- Orlando, FL4 項研究
- Queens, NY4 項研究
Boston 的其他研究
- 乳癌111 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）86 項研究
- 大腸直腸癌63 項研究
- 轉移性癌症63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。